Search

Displaying results 5631 - 5640 of 10000 in total
  1. Drug

    2'-Deoxyuridine

    go.drugbank.com/drugs/DB02256
    Investigational

    An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis.

  2. Drug

    Galicaftor

    go.drugbank.com/drugs/DB14894
    Investigational

    Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737

  3. Drug

    Razuprotafib

    go.drugbank.com/drugs/DB16353
    Investigational

    Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.

  4. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.

  5. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

  6. Drug

    Latrunculin A

    go.drugbank.com/drugs/DB02621
    Investigational

    Latrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer.

    Synonyms: LAT-A, (+)-latrunculin A
  7. Drug

    Camibirstat

    go.drugbank.com/drugs/DB21586
    Investigational

    Camibirstat is a small molecule drug. … Camibirstat has a monoisotopic molecular weight of 562.17 Da.

  8. Drug

    Celivarone

    go.drugbank.com/drugs/DB16012
    Investigational

    Celivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as

  9. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA. … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression.

  10. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia